SCHEMBL16446770

SCHEMBL16446770

COC(=O)c1ccc(-n2ccc3c(C)nc(-c4ccc(OC)c(F)c4)nc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 6/20 0.59
▸ PTK2 Q05397 1/20 0.44
▸ MAPT P10636 1/20 0.42
▸ PTGS1 P23219 2/20 0.40
▸ PTGS2 P35354 2/20 0.40
▸ PIK3CA P42336 2/20 0.40
▸ PIK3CD O00329 1/20 0.40
▸ MTOR P42345 1/20 0.40
▸ PDE4D Q08499 1/20 0.39
▸ GGPS1 O95749 1/20 0.39
▸ RAB9A P51151 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16447005 0.91 PDE4B (0.64) PDE4BPTK2PTGS1PTGS2PIK3CA
SCHEMBL16447006 0.91 PDE4B (0.64) PDE4BPTK2PTGS1PTGS2PIK3CA
SCHEMBL16446446 0.91 PDE4B (0.50) PDE4BPTK2MAPTPIK3CAPIK3CD
SCHEMBL16445876 0.88 PDE4B (0.68) PDE4BPTK2MAPTPTGS1PTGS2
SCHEMBL16448282 0.79 PDE4B (0.64) PDE4BPTK2PTGS1PTGS2RAB9A
SCHEMBL16446612 0.78 PDE4B (0.84) PDE4BPTK2MAPTPTGS1PTGS2
SCHEMBL16446537 0.75 ALDH1A1 (0.43) PDE4BPTK2MAPTALDH1A1SMN1; SMN2
SCHEMBL16446286 0.75 PDE4B (0.45) PDE4BMAPTPTGS1PTGS2PIK3CA
SCHEMBL16446524 0.75 PDE4B (0.79) PDE4BPTGS1PTGS2PDE4D
SCHEMBL16446217 0.74 PDE4B (0.65) PDE4BMAPTPTGS1PTGS2PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP PDE4B 2/4885PTK2 4064/4885MAPT 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback